Teva Pharmaceutical Industries Ltd. has gotten some breathing room with news that the launch of a generic rival to the important 40mg version of its blockbuster multiple sclerosis drug Copaxone (glatiramer) has been delayed due to a manufacturing issue.
An FDA warning letter, made publicly available Feb. 28, cites several manufacturing violations at the Pfizer Inc.-owned facility in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?